Question 1

Is retatrutide a GLP-3, and is GLP-3 RT the same thing?

Accepted Answer

No. GLP-3 is not a receptor, a hormone or a class of compound. The term turns up in search queries and nowhere at all in the published literature. What the literature describes is one molecule acting at three different receptors. A 2026 paper setting out the late-stage trials calls retatrutide a triple agonist activating the glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1 and glucagon receptors. A 2025 review uses the shorter phrase and calls it a novel triple receptor agonist. So the third receptor is glucagon, not a third GLP. Anyone searching for GLP-3, or for GLP-3 RT, is looking for this compound, and the words they will meet in a journal are triple agonist rather than anything with a 3 in it.

Question 2

Is reta a GLP-1?

Accepted Answer

Partly, and partly is the whole answer. One of the three receptors retatrutide acts at is the GLP-1 receptor, which puts it in the same conversation as semaglutide without making it the same kind of molecule. A 2024 review sorts this family by how many receptors each member engages. Semaglutide engages one of them, tirzepatide engages two, and the review lists retatrutide (GLP-1, GIP, and glucagon receptor triple agonist). A 2024 review of gut hormones calls it a triple-agonist of GLP-1, GIP, and glucagon receptor. So calling reta a GLP-1 is accurate and incomplete at the same time. The gap matters when somebody assumes that what is known about a one-receptor compound carries across to a three-receptor one. The glucagon receptor has no counterpart at all among the approved compounds.

Question 3

What is the difference between retatrutide and tirzepatide?

Accepted Answer

One receptor, and a regulatory status. A 2024 review in Diabetes Care names tirzepatide, a GIP-GLP-1 receptor coagonist, and puts retatrutide among the molecules that act at the glucagon receptor as well. So the arithmetic is two receptors against three. The extra one answers glucagon, a hormone that raises blood sugar rather than lowering it. That is a genuinely different lever from anything the approved compound pulls, and it is the part of the design with no counterpart in the older work. The second difference settles most of the practical questions people are really asking. A 2025 review records that tirzepatide has been approved for glycaemic control in type 2 diabetes as well as for obesity management. Retatrutide has not been approved anywhere, for anything.

Question 4

Has retatrutide been compared with tirzepatide in the same trial?

Accepted Answer

No trial among the research behind this page has given both to the same participants, and the reviewers of this literature say so in plain words. A 2025 systematic review searching to October 2024 reported that no head-to-head RCTs were available, and that heterogeneity prevented meta-analysis. The second of those sentences is the one people skip. It means the trials differed enough in design, duration and population that the reviewers declined to pool them into a single figure, and a set of results nobody would pool is a set nobody should rank. One direct comparison is registered and under way. The study of the Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes is listed as ACTIVE_NOT_RECRUITING, meaning recruitment has closed and no result has been published. It runs against semaglutide rather than against tirzepatide.

Question 5

Is retatrutide better than tirzepatide?

Accepted Answer

We do not rank compounds, and here the refusal rests on arithmetic rather than on caution: no study we cite has run the trial that would settle it. What exists instead is three separate margins over placebo, which is exactly why a 2025 systematic review prints them as separate lines. Those lines do point one way. The same review reports that tirzepatide (15 mg once weekly) resulted in weight loss of up to 17.8% (95% CI, 16.3% to 19.3%) after 72 weeks of therapy, while retatrutide (12 mg once weekly) produced greater weight loss of up to 22.1% (CI, 19.3% to 24.9%) after 48 weeks. A 2025 pipeline review reads the same evidence and writes that early data suggests that may lead to even greater WL than tirzepatide. Now read what that is and is not. Larger on average, in a separate trial, in different people, over a different number of weeks, is a different question from better for any particular reader — and one of the two has been approved while the other has not.

Question 6

Is retatrutide stronger than tirzepatide?

Accepted Answer

Stronger is doing several jobs in that question, and they come apart cleanly once separated. If it means a larger average weight change in the trials run so far, a 2024 review describes the whole incretin family as inducing ∼15-24% weight loss in adults with overweight and obesity, and the published retatrutide figures sit at the upper end of that range. If it means more effect per milligram, no study among the research behind this page has measured it, because no trial has given the two compounds at matched amounts to comparable people. If it means more dependable from one person to the next, that is a third question with no published answer either. Those are different questions, and only the first of the three has been measured. The durations alone should slow any comparison down. The retatrutide figure comes from 48 weeks and the tirzepatide figure from 72, and the 2025 review of 26 trials records that treatment ranged from 16 to 104 weeks (median, 43 weeks) across the literature it examined.

Question 7

Retatrutide vs semaglutide: what has been measured?

Accepted Answer

Both have been measured against placebo, and never against each other in anything published. A 2025 systematic review reports semaglutide (2.4 mg once weekly), up to 13.9% (CI, 11.0% to 16.7%) after 68 weeks, against retatrutide at 22.1% after 48 weeks in the same table. Two reviews put the semaglutide figure slightly differently, which is itself informative about how much precision these comparisons carry. A 2025 review of the same trial literature records that semaglutide 2.4 mg once weekly improved weight loss to about 12-15%. Another 2025 review puts the same amount at 15-17% mean weight loss (WL) with evidence of cardioprotection. That last clause has no retatrutide counterpart at all, because no cardiovascular outcome has been published for it. The registered head-to-head is the one to watch, and it runs against semaglutide rather than tirzepatide. Until it reports, the honest description of these two is that they were measured in separate rooms.

Question 8

What about Ozempic, Wegovy, Zepbound and Mounjaro?

Accepted Answer

Those are brand names, and brand names do not appear in the trial literature at all. Journals name molecules, so every figure on this page belongs to semaglutide, tirzepatide, liraglutide or retatrutide rather than to anything printed on a box. That has a practical consequence worth stating plainly. We cannot tell you from the published record which molecule sits behind a particular brand, and we are not going to guess, because a guess about what is inside a package is precisely the kind of thing a reader deserves not to get from us. What can be said is the thing most of those searches are actually after. Retatrutide has no brand name, because a brand belongs to an approved product, and a 2025 systematic review lists it among 9 premarket agents for long-term weight management rather than among the commercially available ones.

Question 9

How does retatrutide differ from survodutide and mazdutide?

Accepted Answer

All three add the glucagon receptor to GLP-1, and only retatrutide adds GIP on top of that. A 2024 review groups it with the first of them, writing that retatrutide and survodutide enable simultaneous activation of the glucagon and GLP-1 receptors, while a 2025 systematic review lists GLP-1/glucagon RAs (mazdutide and survodutide) as a category of their own. So survodutide and mazdutide are two-receptor compounds and retatrutide is a three-receptor one. That is the same structural step as the one between retatrutide and tirzepatide, with a different receptor left out of the pair. None of the three has been approved. The same systematic review records that oral semaglutide 50 mg is the only medication that has completed a phase 3 trial among the emerging agents, which is the state of the field these comparisons are being made inside. No trial among the research behind this page has compared any two of them directly, so each one has been measured against placebo rather than against the others.

Question 10

Is reta safer than tirzepatide or semaglutide?

Accepted Answer

No trial among the research behind this page has compared any of them with harm as its endpoint, so the question has no measured answer and we would not hand down a verdict in any case. What exists is secondary reporting out of trials designed around weight and blood sugar, and similar reporting across a family is not the same thing as a measured comparison inside it. The reporting looks similar across the family. The phase 2 obesity trial recorded that the most common adverse events in the retatrutide groups were gastrointestinal, and the phase 3 diabetes trial concluded with an adverse event profile consistent with molecules with GLP-1 agonist activity. A 2025 systematic review of the class found that AEs requiring treatment discontinuation (0% to 26% vs. 0% to 9%, respectively) and SAEs (0% to 10% vs. 0% to 12%, respectively) were rare. One class-level finding applies to all of them and is easy to miss in a comparison. A 2024 review reports that these agents also cause rapid and significant loss of lean mass (∼10% or ∼6 kg), comparable to a decade or more of aging, in adults taking them, and no trial among the research behind this page has set the compounds against each other on that. A class-level comparison of body composition does exist, and the GLP-1 safety page carries it.

Question 11

Can you switch from tirzepatide or semaglutide to retatrutide?

Accepted Answer

No trial among the research behind this page has studied a switch, and the trials were built in a way that excluded the situation. The phase 2 diabetes trial enrolled people who were treated with diet and exercise alone or with a stable dose of metformin (≥1000 mg once daily) for at least 3 months before the screening visit, and the phase 3 trial recruited adults whose diabetes was inadequately controlled by diet and exercise alone. Read what that does to the published figures. Every weight and blood-sugar result for retatrutide was measured in participants who were not already taking one of these compounds, so none of it describes what happens to somebody well into a course of something else. Whether a switch makes sense for a reader is a clinical question and not one we answer. What can be said is that every retatrutide figure was measured against placebo rather than against the compound a reader is already taking.

Question 12

Can retatrutide and tirzepatide be taken together?

Accepted Answer

No trial among the research behind this page has given both to the same person, so there is no result to report and no interaction to describe. Every trial in the published record assigned one compound, an active comparator or a placebo. The nearest thing on record is a design idea rather than a pairing of finished injections. A 2025 review describes the strategy as combinations of GLP-1 with other entero-pancreatic hormones with complementary actions and/or synergistic potential, which is how a single molecule like retatrutide came to exist at all. Read that distinction carefully, because it is doing real work. Building several receptor actions into one molecule and then testing that molecule is not the same thing as stacking two finished compounds, and no study we could find has tested the second in anybody.

Question 13

How does the strength of the evidence compare?

Accepted Answer

This is the comparison that can actually be made, and it does not run in retatrutide's favour. Tirzepatide and semaglutide have completed late-stage programmes and been approved, while retatrutide has one published phase 3 trial and four more still running. A 2025 systematic review of 26 RCTs comprising 15 491 participants put all of these compounds in one frame and then declined to combine them, on the grounds that heterogeneity prevented meta-analysis. A 2025 systematic review of the pipeline counts retatrutide among 14 ongoing phase 3 trials on glucagon-like peptide-1 (GLP-1) receptor agonists (RAs). So the compound with the largest published average weight change also has the thinnest record standing behind it. Those two facts are usually reported in separate places, and holding them together is most of what a comparison is good for.

Question 14

How do the approval statuses compare?

Accepted Answer

This is the only part of the comparison that is settled. A 2025 systematic review split the agents it examined into three that are already on sale and 9 premarket agents for long-term weight management. Retatrutide sits in the second group, along with most of the pipeline. The ones on sale have dates attached. A 2025 review records semaglutide at 2.4 mg once weekly as approved for obesity treatment in 2021, and tirzepatide as approved for glycaemic control in type 2 diabetes as well as for obesity management. For retatrutide the matching entry is an enforcement record rather than an approval. The FDA database holds one Class II recall of a compounded 60mg / 10mL vial, filed under lack of assurance of sterility. A gap that wide is not a judgement about either molecule, and it is a real difference in how much is known about what goes into a vial.

Retatrutide comparisons and stacks